ClinicalTrials.gg
CompletedNCT03978832Updated Jul 7, 2021Results posted

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

A Phase 4 interventional study of PERSERIS and Risperidone in Schizophrenia, sponsored by Indivior Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by Indivior Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
69
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
86th of 123
69 · median 100
Started
2019
with 2 others
Phase 4
63 of 127
2 open now
Registered
118th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 86th largest by enrollment of the 123 interventional ones that give a count, is one of 3 that started in 2019, is one of 63 in phase 4, and was the 118th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

This study evaluates PERSERIS at a higher dose than what has been administered in previous clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will be switched to PERSERIS at the higher dose, which is believed to be similar to the oral dose

Read the detailed description

PERSERIS is an extended-release subcutaneous (SC) injectable suspension administered monthly for the treatment of schizophrenia in adults. PERSERIS was approved by the FDA at doses equivalent to 3 mg and 4 mg oral risperidone. Many patients require doses of 5-6 mg oral risperidone and above, and this study will test a higher dose of PERSERIS in order to meet this need.

Eligible subjects will initially be stabilized in the clinical unit on 6 mg oral risperidone for 5 days and transition to an approximate dose of PERSERIS by SC injection. PERSERIS will be administered every 28 days and subjects will be admitted to the clinical unit the day before, and remain in the unit for 3 days after each injection for pharmacokinetics (PK) and safety evaluations (a total of 8 days for the first injection including the stabilization period). Subjects will return to the clinic between injections for additional PK, safety and efficacy assessments at scheduled intervals until the next injection.

A total of 4 doses of PERSERIS will be administered. The 4th dose will evaluate an alternate site for injection, and will be administered in the back of the upper arm.

Subjects will return to the clinical unit for an end of study visit and will receive a follow up phone call to assess for adverse events one week after the end of study visit.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia
  • Clinically stable as defined as no hospitalizations for acute exacerbations within 3 months of screening and Screening PANSS score ≤70
  • Total (BMI) between 18 and 35 kg/m2
  • Given written

Exclusion criteria

Exclusion Criteria:

  • Received a once-monthly long-acting injectable (LAI) antipsychotic within 60 days of screening and a once every 3 month LAI antipsychotic within 120 days of screening
  • Taking the following concurrent or over the counter (OTC) products:

    1. Inducers or inhibitors of CYP2D6 within 14 days or 5 half-lives whichever is greater prior to study screening
    2. Bupropion, chlorpheniramine, cimetidine, clomipramine, doxepin or quinidine within 30 days prior to study screening
    3. Clozapine, phenothiazines, aripiprazole, haloperidol or any other antipsychotic other than oral risperidone within 14 days prior to study screening
    4. Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) within 30 days prior to study screening
    5. Opioids or opioid-containing analgesics within 14 days prior to study screening
    6. Medications, in the addition to those listed above which in the opinion of the Investigator in conjunction with the medical monitor, may be expected to significantly interfere with the metabolism or excretion of risperidone and/or 9-hydroxyrisperidone, that may be associated with a significant drug interaction with risperidone, or that may pose a significant risk to subjects' participation in the study. The medical monitor should be contacted with any questions regarding the use of CYP2D6 or 3A4 inducers or inhibitors in particular.
  • History of cancer (with the exception of resected basal cell or squamous cell carcinoma of the skin) unless they have been disease free for ≥5 years.
  • Another active medical condition or organ disease that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug.
  • Evidence or history of a significant hepatic disorder that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug. Individuals with acute or chronic hepatitis (including but not limited to or C); or individuals with 1) total >1.5x the (ULN) and/or 2) (ALT) or aspartate aminotransferase (AST) >3x ULN will be excluded.
  • A history of renal disease, or a of less than 60 mL/min (as determined by the Cockcroft-Gault formula).
  • A history of orthostatic hypotension, syncope, significant low white blood cell (WBC) count (i.e., based on or drug-induced leukopenia or other medical conditions including, but not limited to, history of heart attack (i.e., myocardial infarction) or brain injury (i.e., traumatic with loss of consciousness and/or cardiovascular accident) within a year of Screening and low blood pressure or arrhythmias as interpreted by the principal investigator (PI).
  • interval [Fridericia's calculation (QTcF)] >450 msec (male) or >470 msec (female) at screening or prior to administration of the 1st dose of PERSERIS, or with a known history of Torsades de Points, or family member with sudden unexplained cardiac death.
  • Known to have AIDS (acquired immunodeficiency syndrome) or to be (human immunodeficiency virus) positive.
  • Suicidal ideation with intent and plan, as assessed by affirmative answers to C-SSRS questions 4 and 5 of the ideation section,or suicide attempts within the last 6 months as noted on the C-SSRS, or subjects with uncontrolled depression in the opinion of the Investigator.
  • Known diagnosis of type 1 diabetes or subjects with (HbA1c) >8.0% at screening.
  • Participated in a clinical trial within 30 days prior to study screening.
  • Significant traumatic injury, major surgery or open within 30 days prior to study screening.
  • Meet the criteria for the diagnosis of current moderate or severe substance use disorder.
  • Prior allergic reactions, sensitivities, or other known to any component of PERSERIS.
  • Women of who are pregnant or breastfeeding, seeking pregnancy or failing to use adequate methods during the study.
  • Positive urine drug screen (UDS) anytime through Day -1 for opioids, cocaine, amphetamines, methadone, cannabinoids, barbiturates, benzodiazepines, methamphetamine and phencyclidine, unless the positive screen is determined to be secondary to an allowable concomitant medication. If a positive UDS is possibly the result of a subject's use of OTC or prescription medications, a repeat urine drug screen may be permissible. Study site personnel should contact the medical monitor for approval to retest.
  • Tardive dyskinesia as assessed by a score of ≥2 on Item 8 of the Abnormal Involuntary Movement Scale (AIMS) at Screening.
  • Epilepsy or other seizure disorders, Parkinson's disease or dementia.
  • History of neuroleptic malignant syndrome.
  • Previously injected with PERSERIS within 6 months prior to screening.
  • Unable, in the opinion of the PI, to comply fully with the study requirements.
  • Determined to be poor metabolisers, intermediate metabolisers or ultra-rapid metabolisers for CYP2D6 genotype.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Oral Risperidone followed by PERSERIS

    All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.

    Drug: PERSERIS · Drug: Risperidone

Interventions

  • PERSERIS is an extended-release SC injectable suspension administered once-monthly

    Also known as: long acting risperidone

  • Oral risperidone

    Also known as: Risperdal

06

What researchers measure

Primary outcomes

  1. Steady-state Average Plasma Concentration (Cavg,ss) of Risperidone and Total Active Moiety

    Cavg,ss for risperidone and total active moiety after oral and SC administration

    Time frame: 0-12 hours post-dose on Day -1, and 0-672 hours after Dose 3

Secondary outcomes

  1. Assessment of Local Injection Site Tolerability*

    Injection site tolerability was measured by injection site grading for redness, induration, swelling and tenderness/pain. These were graded on a scale from 0 to 4 for severity (none, mild, moderate, severe and potentially life-threatening)

    Time frame: First injection at Day 1 until last injection administered at Day 85

  2. The Number of Participants With TEAEs as Assessed by Local Injection Site*

    The injection site was evaluated for adverse events by observation and examination by appropriately trained personnel.

    Time frame: First injection at Day 1 until Day 120

  3. The Number of Participants With TEAEs as Assessed by Changes in Vital Signs

    Vital sign measurement was performed, including orthostatic blood pressure, and clinically significant changes were reported as adverse events (AE). Vital sign measurement also included measurement of pulse rate, oral temperature and respiratory rate. Determination of whether the changes were AEs was made by the investigator or a medically qualified designee. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range and the subject was clinically stable, a specific diagnosis was established, or the condition otherwise explained.

    Time frame: Time subjects sign the informed consent form throughout the study until EOS (Day 113)

  4. The Number of Participants With TEAEs as Assessed by Changes in ECG

    ECGs were performed, and clinically significant changes in parameters were reported as adverse events (AE). ECGs were performed after 5 minutes of rest, and ECG parameters including QT interval, PR interval, QRS interval and heart rate was recorded. The ECG measurements were evaluated during the visit and determination of whether any abnormalities were AEs was made by the investigator or a medically qualified designee. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range and the subject was clinically stable, a specific diagnosis was established, or the condition otherwise explained.

    Time frame: Time participants sign the informed consent form throughout the study until EOS (Day 113)

  5. The Number of Participants With TEAEs as Assessed by Changes in Body Weight

    Body weight, with shoes off, was measured and clinically significant changes in weight was reported as adverse events (AE). Determination of whether the changes were AEs was made by the investigator or a medically qualified designee. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range and the subject was clinically stable, a specific diagnosis was established, or the condition otherwise explained.

    Time frame: Time subjects sign the informed consent form throughout the study until EOS (Day 113)

  6. The Number of Participants With TEAEs as Assessed by Changes in Laboratory Testing

    Laboratory testing was performed by the local clinical laboratory accredited by the College of American Pathologists, and clinically significant changes from baseline were reported as AEs. Subjects were expected to fast for a minimum of 8 hours prior to blood draws for all laboratory assessments except at the screening visit. Prior to entering the study, any abnormal laboratory test results were to be considered not clinically significant. Any abnormal hematology, serum chemistry or urinalysis test result after study drug intake that was determined by the investigator or a medically qualified designee to be clinically significant was reported as an AE. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range or it was determined that resolution was not expected.

    Time frame: Time subjects sign the informed consent form throughout the study until end of study (EOS) visit (Day 113)

  7. The Number of Participants With TEAEs as Assessed by Extrapyramidal Symptoms (EPS) of Anti-psychotic Drug Treatment

    Safety of treatment was measured by administration of symptom questionnaires including AIMS, Barnes Akathisia Rating Scale (BARS) and Simpson-Angus Scale (SAS), as well as by assessment by the investigator or suitably qualified medical designee. The AIMS is a tool that aids in early detection and ongoing monitoring of tardive dyskinesia, a movement disorder. The BARS is a 4-item scale that detects the presence and severity of any drug-induced restlessness. The SAS is a 10-item scale used to detect the presence of drug-induced Parkinsonism (movement disorder seen in Parkinson's disease) and extrapyramidal side effects and evaluates symptom severity. Extrapyramidal symptoms include involuntary or uncontrollable movements, tremors, and muscle contractions.

    Time frame: Time subjects sign the informed consent form throughout the study until EOS (Day 113)

  8. Positive and Negative Syndrome Scale (PANSS)

    Clinical outcome (efficacy endpoint) as measured by change from baseline in PANSS scores was measured. PANSS is a medical scale designed to measure schizophrenia symptom severity utilizing a 30 item, 7-point rating scheme. The PANSS Is scored by a summation of ratings across items, with a total potential range of 7-210; higher results indicate greater severity of illness. Only total score changes from baseline are reported here.

    Time frame: Baseline, defined as last assessment prior to first injection, through Day 113 (EOS)

  9. Clinical Global Impression-Severity of Illness Scale (CGI-S)

    Clinical outcome (efficacy endpoint) as measured by change from baseline in CGI-S scores was measured. The CGI-S is a measurement of the total severity of illness where one question is assessed. Responses range from 0 (not assessed) to 7 (most extremely ill).

    Time frame: Baseline through EOS (Day 113)

  10. Columbia-Suicide Severity Rating Scale (C-SSRS)-Change

    Significant changes from baseline in C-SSRS scores were reported as adverse events. The C-SSRS is based on a categorization of thoughts and behavior that are identified as related to suicidal behavior. The scale captures the occurrence, severity and frequency of suicide related thoughts and behaviors throughout lifetime at screening and for the time interval since last administration during a study. Responses are indicated as yes (thought or behavior did occur) or no (thought or behavior did not occur). If a yes response is received, then follow up questions are asked. The outcome of the C-SSRS is a numerical score obtained from each of the categories. Scores can range from 0-25, indicating the intensity rating, and any score greater than 0 may indicate the need for mental health intervention. Higher scores indicate greater intensity (i.e. worse outcome).

    Time frame: Screening through EOS (Day 113)

  11. Safety as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) Scores

    Safety of treatment was measured by characterization of thoughts and behavior related to suicidal behavior. This was assessed by administration of the C-SSRS at designated visits. The scale captures the occurrence, severity and frequency of suicide related thoughts and behaviours throughout lifetime at screening and for the time interval since last administration during a study. Questions solicit the type of information needed to determine if a suicide-related thought or behavior occurred.

    Time frame: Screening through EOS (Day 113)

  12. Minimum Plasma Concentration Over the Dosing Interval

    Minimum observed plasma concentration of risperidone, 9-hydroxyrisperidone (9-OH) and total active moiety over the dosing interval after oral dosing and SC doses 1, 3 and 4

    Time frame: Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).

  13. Maximum Plasma Concentration Over the Dosing Interval

    Maximum observed plasma concentration of risperidone, 9-hydroxyrisperidone (9-OH) and total active moiety over the dosing interval after oral dosing and SC doses 1, 3 and 4

    Time frame: Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4)

  14. Percent Fluctuation in Concentration Over the Dosing Interval

    Plasma concentration variation of risperidone, 9-OH and total active moiety over the dosing interval was measured by percent fluctuation after oral dosing and SC doses 1, 3 and 4 at steady state.

    Time frame: Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4)

  15. Area Under the Plasma Concentration-time Curve Over the Dosing Interval

    Area under the plasma concentration-time curve (AUC) was measured for risperidone, 9-OH and total active moiety.

    Time frame: Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).

  16. Average Plasma Concentration (Cavg) Over the Dosing Interval of Risperidone, 9-OH and Total Active Moiety

    Average plasma concentration of risperidone, 9-hydroxyrisperidone (9-OH) and total active moiety over the dosing interval after oral dosing and SC doses 1, 3 and 4.

    Time frame: Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).

  17. Trough Plasma Concentration

    Trough (pre-dose) plasma concentrations were measured for risperidone, 9-OH and total active moiety for SC doses 1, 3 and 4

    Time frame: Calculated over the dosing interval (0-672 hours) after Dose 1, 3 or 4.

  18. Time to Occurrence of Maximum Concentration

    Time to maximal observed plasma concentration (Tmax) for risperidone, 9-OH, and total active moiety after oral dosing and SC doses 1, 3 and 4.

    Time frame: Calculated over the overall dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).

07

Results

Posted Jul 7, 2021

Participant flow

The study recruited participants from the community between June and December 2019. Participants were on a stable dose of 5 mg or 6 mg of oral risperidone daily; any daily or twice daily dosing combination was acceptable.

Participant flow — Overall Study
MilestoneOral Risperidone Followed by PERSERIS
Started69
Stabilization period25
Treatment period23
Completed15
Not completed54
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject6
Withdrew: Physician decision2
Withdrew: Did not pass screening criteria44

Outcome measures

PrimarySteady-state Average Plasma Concentration (Cavg,ss) of Risperidone and Total Active Moiety

Cavg,ss for risperidone and total active moiety after oral and SC administration

Time frame:
0-12 hours post-dose on Day -1, and 0-672 hours after Dose 3
Reported as:
Geometric mean · ng/mL
Steady-state Average Plasma Concentration (Cavg,ss) of Risperidone and Total Active Moiety
ng/mLOral Risperidone Followed by PERSERIS
Risperidone after oral dosing5.150 ± 43.3
Risperidone after Dose 310.200 ± 65.3
Total active moiety after oral dosing43.730 ± 34.8
Total active moiety after Dose 344.049 ± 24.4
SecondaryAssessment of Local Injection Site Tolerability*

Injection site tolerability was measured by injection site grading for redness, induration, swelling and tenderness/pain. These were graded on a scale from 0 to 4 for severity (none, mild, moderate, severe and potentially life-threatening)

Time frame:
First injection at Day 1 until last injection administered at Day 85
Reported as:
Count of participants · Participants
Assessment of Local Injection Site Tolerability*
ParticipantsOral Risperidone Followed by PERSERIS
Dose 1 injection site pain grade — None22
Dose 1 injection site pain grade — Mild1
Dose 2 injection site pain grade — None19
Dose 2 injection site pain grade — Mild1
Dose 3 injection site pain grade — None16
Dose 3 injection site pain grade — Mild0
Dose 4 injection site pain grade — None15
Dose 4 injection site pain grade — Mild1
Dose 1 injection site tenderness grade — None21
Dose 1 injection site tenderness grade — Mild2
Dose 2 injection site tenderness grade — None18
Dose 2 injection site tenderness grade — Mild2
Dose 3 injection site tenderness grade — None15
Dose 3 injection site tenderness grade — Mild1
Dose 4 injection site tenderness grade — None13
Dose 4 injection site tenderness grade — Mild3
Dose 1 injection site erythema/redness grade — None22
Dose 1 injection site erythema/redness grade — Mild1
Dose 2 injection site erythema/redness grade — None20
Dose 2 injection site erythema/redness grade — Mild0
Dose 3 injection site erythema/redness grade — None16
Dose 3 injection site erythema/redness grade — Mild0
Dose 4 injection site erythema/redness grade — None16
Dose 4 injection site erythema/redness grade — Mild0
Dose 1 injection site induration/swelling grade — None23
Dose 1 injection site induration/swelling grade — Mild0
Dose 2 injection site induration/swelling grade — None20
Dose 2 injection site induration/swelling grade — Mild0
Dose 3 injection site induration/swelling grade — None15
Dose 3 injection site induration/swelling grade — Mild1
Dose 4 injection site induration/swelling grade — None14
Dose 4 injection site induration/swelling grade — Mild2
SecondaryThe Number of Participants With TEAEs as Assessed by Local Injection Site*

The injection site was evaluated for adverse events by observation and examination by appropriately trained personnel.

Time frame:
First injection at Day 1 until Day 120
Reported as:
Count of participants · Participants
The Number of Participants With TEAEs as Assessed by Local Injection Site*
ParticipantsOral Risperidone Followed by PERSERIS
The Number of Participants With TEAEs as Assessed by Local Injection Site*1
SecondaryThe Number of Participants With TEAEs as Assessed by Changes in Vital Signs

Vital sign measurement was performed, including orthostatic blood pressure, and clinically significant changes were reported as adverse events (AE). Vital sign measurement also included measurement of pulse rate, oral temperature and respiratory rate. Determination of whether the changes were AEs was made by the investigator or a medically qualified designee. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range and the subject was clinically stable, a specific diagnosis was established, or the condition otherwise explained.

Time frame:
Time subjects sign the informed consent form throughout the study until EOS (Day 113)
Reported as:
Count of participants · Participants
The Number of Participants With TEAEs as Assessed by Changes in Vital Signs
ParticipantsOral Risperidone Followed by PERSERIS
The Number of Participants With TEAEs as Assessed by Changes in Vital Signs1
SecondaryThe Number of Participants With TEAEs as Assessed by Changes in ECG

ECGs were performed, and clinically significant changes in parameters were reported as adverse events (AE). ECGs were performed after 5 minutes of rest, and ECG parameters including QT interval, PR interval, QRS interval and heart rate was recorded. The ECG measurements were evaluated during the visit and determination of whether any abnormalities were AEs was made by the investigator or a medically qualified designee. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range and the subject was clinically stable, a specific diagnosis was established, or the condition otherwise explained.

Time frame:
Time participants sign the informed consent form throughout the study until EOS (Day 113)
Reported as:
Count of participants · Participants
The Number of Participants With TEAEs as Assessed by Changes in ECG
ParticipantsOral Risperidone Followed by PERSERIS
The Number of Participants With TEAEs as Assessed by Changes in ECG0
SecondaryThe Number of Participants With TEAEs as Assessed by Changes in Body Weight

Body weight, with shoes off, was measured and clinically significant changes in weight was reported as adverse events (AE). Determination of whether the changes were AEs was made by the investigator or a medically qualified designee. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range and the subject was clinically stable, a specific diagnosis was established, or the condition otherwise explained.

Time frame:
Time subjects sign the informed consent form throughout the study until EOS (Day 113)
Reported as:
Count of participants · Participants
The Number of Participants With TEAEs as Assessed by Changes in Body Weight
ParticipantsOral Risperidone Followed by PERSERIS
The Number of Participants With TEAEs as Assessed by Changes in Body Weight1
SecondaryThe Number of Participants With TEAEs as Assessed by Changes in Laboratory Testing

Laboratory testing was performed by the local clinical laboratory accredited by the College of American Pathologists, and clinically significant changes from baseline were reported as AEs. Subjects were expected to fast for a minimum of 8 hours prior to blood draws for all laboratory assessments except at the screening visit. Prior to entering the study, any abnormal laboratory test results were to be considered not clinically significant. Any abnormal hematology, serum chemistry or urinalysis test result after study drug intake that was determined by the investigator or a medically qualified designee to be clinically significant was reported as an AE. If determined to be an AE, the measurement was repeated at appropriate intervals until the value returned to an acceptable range or it was determined that resolution was not expected.

Time frame:
Time subjects sign the informed consent form throughout the study until end of study (EOS) visit (Day 113)
Reported as:
Count of participants · Participants
The Number of Participants With TEAEs as Assessed by Changes in Laboratory Testing
ParticipantsOral Risperidone Followed by PERSERIS
The Number of Participants With TEAEs as Assessed by Changes in Laboratory Testing3
SecondaryThe Number of Participants With TEAEs as Assessed by Extrapyramidal Symptoms (EPS) of Anti-psychotic Drug Treatment

Safety of treatment was measured by administration of symptom questionnaires including AIMS, Barnes Akathisia Rating Scale (BARS) and Simpson-Angus Scale (SAS), as well as by assessment by the investigator or suitably qualified medical designee. The AIMS is a tool that aids in early detection and ongoing monitoring of tardive dyskinesia, a movement disorder. The BARS is a 4-item scale that detects the presence and severity of any drug-induced restlessness. The SAS is a 10-item scale used to detect the presence of drug-induced Parkinsonism (movement disorder seen in Parkinson's disease) and extrapyramidal side effects and evaluates symptom severity. Extrapyramidal symptoms include involuntary or uncontrollable movements, tremors, and muscle contractions.

Time frame:
Time subjects sign the informed consent form throughout the study until EOS (Day 113)
Reported as:
Count of participants · Participants
The Number of Participants With TEAEs as Assessed by Extrapyramidal Symptoms (EPS) of Anti-psychotic Drug Treatment
ParticipantsOral Risperidone Followed by PERSERIS
Akathisia1
Dyskinesia2
Parkinsonian gait1
Tremor1
SecondaryPositive and Negative Syndrome Scale (PANSS)

Clinical outcome (efficacy endpoint) as measured by change from baseline in PANSS scores was measured. PANSS is a medical scale designed to measure schizophrenia symptom severity utilizing a 30 item, 7-point rating scheme. The PANSS Is scored by a summation of ratings across items, with a total potential range of 7-210; higher results indicate greater severity of illness. Only total score changes from baseline are reported here.

Time frame:
Baseline, defined as last assessment prior to first injection, through Day 113 (EOS)
Reported as:
Mean · score on a scale
Positive and Negative Syndrome Scale (PANSS)
score on a scaleOral Risperidone Followed by PERSERIS
Total score change from baseline: Dose 1 Day 2-0.2 ± 3.52
Total score change from baseline: Dose 1 Day 80.9 ± 3.91
Total score change from baseline: Dose 1 Day 150.7 ± 4.81
Total score change from baseline: Dose 1 Day 22-0.4 ± 4.16
Total score change from baseline: Dose 2 Day 29-0.9 ± 5.05
Total score change from baseline: Dose 2 Day 50-0.5 ± 7.21
Total score change from baseline: Dose 3 Day 57-2.9 ± 4.92
Total score change from baseline: Dose 4 Day 85-0.9 ± 6.00
Total score change from baseline: Day 113-EOS1.6 ± 6.22
SecondaryClinical Global Impression-Severity of Illness Scale (CGI-S)

Clinical outcome (efficacy endpoint) as measured by change from baseline in CGI-S scores was measured. The CGI-S is a measurement of the total severity of illness where one question is assessed. Responses range from 0 (not assessed) to 7 (most extremely ill).

Time frame:
Baseline through EOS (Day 113)
Reported as:
Mean · score on a scale
Clinical Global Impression-Severity of Illness Scale (CGI-S)
score on a scaleOral Risperidone Followed by PERSERIS
Change from baseline: Dose 1/Day 2-0.1 ± 0.29
Change from baseline: Dose 1/Day 80.0 ± 0.21
Change from baseline: Dose 1/Day 150.0 ± 0.38
Change from baseline: Dose 1/Day 220.0 ± 0.44
Change from baseline: Dose 2/Day 290.0 ± 0.44
Change from baseline: Dose 2/Day 500.0 ± 0.47
Change from baseline: Dose 3/Day 570.1 ± 0.44
Change from baseline: Dose 4/Day 850.1 ± 0.50
Change from baseline: EOS/Day 1130.0 ± 0.55
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)-Change

Significant changes from baseline in C-SSRS scores were reported as adverse events. The C-SSRS is based on a categorization of thoughts and behavior that are identified as related to suicidal behavior. The scale captures the occurrence, severity and frequency of suicide related thoughts and behaviors throughout lifetime at screening and for the time interval since last administration during a study. Responses are indicated as yes (thought or behavior did occur) or no (thought or behavior did not occur). If a yes response is received, then follow up questions are asked. The outcome of the C-SSRS is a numerical score obtained from each of the categories. Scores can range from 0-25, indicating the intensity rating, and any score greater than 0 may indicate the need for mental health intervention. Higher scores indicate greater intensity (i.e. worse outcome).

Time frame:
Screening through EOS (Day 113)
Reported as:
Mean · score on a scale
Columbia-Suicide Severity Rating Scale (C-SSRS)-Change
score on a scaleOral Risperidone Followed by PERSERIS
Change in Maximum Suicidal Ideation at Dose 1/Day 80.0 ± 0.00
Change in Maximum Suicidal Ideation at EOS0.0 ± 0.00
Change in Suicidal Ideation Intensity Score at Dose 1/Day 80.0 ± 0.00
Change in Suicidal Ideation Intensity Score at EOS0.0 ± 0.00
Change in Maximum Suicidal Behavior at Dose 1/Day 80.0 ± 0.00
Change in Maximum Suicidal Behavior at EOS0.0 ± 0.00
SecondarySafety as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) Scores

Safety of treatment was measured by characterization of thoughts and behavior related to suicidal behavior. This was assessed by administration of the C-SSRS at designated visits. The scale captures the occurrence, severity and frequency of suicide related thoughts and behaviours throughout lifetime at screening and for the time interval since last administration during a study. Questions solicit the type of information needed to determine if a suicide-related thought or behavior occurred.

Time frame:
Screening through EOS (Day 113)
Reported as:
Count of participants · Participants
Safety as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) Scores
ParticipantsOral Risperidone Followed by PERSERIS
Any Suicidal Ideation - Lifetime — No15
Any Suicidal Ideation - Lifetime — Yes8
Any Suicidal Ideation - Past 6 months — No23
Any Suicidal Ideation - Past 6 months — Yes0
Any Suicidal Ideation - EOS — No14
Any Suicidal Ideation - EOS — Yes0
Any Suicidal Behavior - Lifetime — No17
Any Suicidal Behavior - Lifetime — Yes6
Any Suicidal Behavior - Past 6 months — No20
Any Suicidal Behavior - Past 6 months — Yes0
Any Suicidal Behavior - EOS — No14
Any Suicidal Behavior - EOS — Yes0
Any Suicidal Ideation or Behavior - Lifetime — No15
Any Suicidal Ideation or Behavior - Lifetime — Yes8
Any Suicidal Ideation or Behavior - Past 6 months — No20
Any Suicidal Ideation or Behavior - Past 6 months — Yes0
Any Suicidal Ideation or Behavior - EOS — No14
Any Suicidal Ideation or Behavior - EOS — Yes0
SecondaryMinimum Plasma Concentration Over the Dosing Interval

Minimum observed plasma concentration of risperidone, 9-hydroxyrisperidone (9-OH) and total active moiety over the dosing interval after oral dosing and SC doses 1, 3 and 4

Time frame:
Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).
Reported as:
Geometric mean · ng/mL
Minimum Plasma Concentration Over the Dosing Interval
ng/mLOral Risperidone Followed by PERSERIS
Risperidone after oral dosing1.066 ± 89.0
Risperidone after Dose 13.017 ± 39.0
Risperidone after Dose 34.519 ± 48.1
Risperidone after Dose 45.020 ± 48.7
9-OH after oral dosing27.705 ± 41.7
9-OH after Dose 113.922 ± 63.6
9-OH after Dose 316.951 ± 41.6
9-OH after Dose 414.820 ± 46.3
Total active moiety after oral dosing28.329 ± 39.6
Total active moiety after Dose 117.852 ± 55.8
Total active moiety after Dose 322.250 ± 37.7
Total active moiety after Dose 422.063 ± 35.7
SecondaryMaximum Plasma Concentration Over the Dosing Interval

Maximum observed plasma concentration of risperidone, 9-hydroxyrisperidone (9-OH) and total active moiety over the dosing interval after oral dosing and SC doses 1, 3 and 4

Time frame:
Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4)
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration Over the Dosing Interval
ng/mLOral Risperidone Followed by PERSERIS
Risperidone after oral dosing14.052 ± 45.2
Risperidone after Dose 116.743 ± 57.1
Risperidone after Dose 318.635 ± 54.6
Risperidone after Dose 429.821 ± 65.1
9-OH after oral dosing45.464 ± 40.0
9-OH after Dose 145.285 ± 43.3
9-OH after Dose 356.476 ± 34.5
9-OH after Dose 452.240 ± 27.4
Total active moiety after oral dosing58.453 ± 33.5
Total active moiety after Dose 158.317 ± 38.4
Total active moiety after Dose 370.597 ± 30.7
Total active moiety after Dose 477.219 ± 32.5
SecondaryPercent Fluctuation in Concentration Over the Dosing Interval

Plasma concentration variation of risperidone, 9-OH and total active moiety over the dosing interval was measured by percent fluctuation after oral dosing and SC doses 1, 3 and 4 at steady state.

Time frame:
Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4)
Reported as:
Geometric mean · percentage of fluctuation
Percent Fluctuation in Concentration Over the Dosing Interval
percentage of fluctuationOral Risperidone Followed by PERSERIS
Risperidone after oral dosing253.335 ± 33.6
Risperidone after Dose 1174.653 ± 35.4
Risperidone after Dose 3135.267 ± 19.6
Risperidone after Dose 4190.117 ± 66.7
9-OH after oral dosing46.787 ± 32.0
9-OH after Dose 1115.645 ± 48.1
9-OH after Dose 3115.286 ± 55.5
9-OH after Dose 4116.852 ± 44.7
Total active moiety after oral dosing71.468 ± 26.0
Total active moiety after Dose 1115.113 ± 29.2
Total active moiety after Dose 3106.210 ± 28.6
Total active moiety after Dose 4118.435 ± 34.5
SecondaryArea Under the Plasma Concentration-time Curve Over the Dosing Interval

Area under the plasma concentration-time curve (AUC) was measured for risperidone, 9-OH and total active moiety.

Time frame:
Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve Over the Dosing Interval
hr*ng/mLOral Risperidone Followed by PERSERIS
Risperidone after oral dosing60.354 ± 54.4
Risperidone after Dose 15021.191 ± 55.0
Risperidone after Dose 36854.855 ± 65.2
Risperidone after Dose 47762.268 ± 63.6
9-OH after oral dosing432.801 ± 38.4
9-OH after Dose 117615.97 ± 44.0
9-OH after Dose 322203.31 ± 28.9
9-OH after Dose 420527.19 ± 30.2
Total active moiety after oral dosing489.888 ± 34.0
Total active moiety after Dose 122955.74 ± 37.5
Total active moiety after Dose 329602.72 ± 24.4
Total active moiety after Dose 429217.83 ± 23.4
SecondaryAverage Plasma Concentration (Cavg) Over the Dosing Interval of Risperidone, 9-OH and Total Active Moiety

Average plasma concentration of risperidone, 9-hydroxyrisperidone (9-OH) and total active moiety over the dosing interval after oral dosing and SC doses 1, 3 and 4.

Time frame:
Calculated over the dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).
Reported as:
Geometric mean · ng/mL
Average Plasma Concentration (Cavg) Over the Dosing Interval of Risperidone, 9-OH and Total Active Moiety
ng/mLOral Risperidone Followed by PERSERIS
Risperidone after oral dosing5.030 ± 54.4
Risperidone after Dose 17.454 ± 55.2
Risperidone after Dose 310.200 ± 65.3
Risperidone after Dose 411.618 ± 63.2
9-OH after oral dosing36.066 ± 38.4
9-OH after Dose 126.148 ± 44.0
9-OH after Dose 333.039 ± 28.8
9-OH after Dose 430.723 ± 31.3
Total active moiety after oral dosing40.823 ± 34.0
Total active moiety after Dose 134.077 ± 37.5
Total active moiety after Dose 344.049 ± 24.4
Total active moiety after Dose 443.729 ± 24.0
SecondaryTrough Plasma Concentration

Trough (pre-dose) plasma concentrations were measured for risperidone, 9-OH and total active moiety for SC doses 1, 3 and 4

Time frame:
Calculated over the dosing interval (0-672 hours) after Dose 1, 3 or 4.
Reported as:
Geometric mean · ng/mL
Trough Plasma Concentration
ng/mLOral Risperidone Followed by PERSERIS
Risperidone after Dose 11.766 ± 117.9
Risperidone after dose 35.066 ± 48.0
Risperidone after Dose 44.966 ± 62.9
9-OH after dose 133.696 ± 37.9
9-OH after dose 320.326 ± 51.0
9-OH after dose 417.983 ± 39.2
Total active moiety after dose 135.553 ± 35.6
Total active moiety after dose 325.468 ± 43.0
Total active moiety after dose 423.125 ± 37.3
SecondaryTime to Occurrence of Maximum Concentration

Time to maximal observed plasma concentration (Tmax) for risperidone, 9-OH, and total active moiety after oral dosing and SC doses 1, 3 and 4.

Time frame:
Calculated over the overall dosing interval (0-12 hours on Day -1, or 0-672 hours after Dose 1, 3 or 4).
Reported as:
Median · hr
Time to Occurrence of Maximum Concentration
hrOral Risperidone Followed by PERSERIS
Risperidone after oral dosing1.0 (0.50 to 4.00)
Risperidone after Dose 1240.175 (4.03 to 576.23)
Risperidone after Dose 3143.865 (2.03 to 503.32)
Risperidone after Dose 412.050 (2.03 to 383.87)
9-OH after oral dosing1.990 (0.50 to 5.83)
9-OH after Dose 1204.515 (2.03 to 406.48)
9-OH after Dose 3182.535 (23.03 to 336.32)
9-OH after Dose 4118.120 (22.03 to 406.90)
Total active moiety after oral dosing1.010 (0.50 to 4.00)
Total active moiety after Dose 1239.665 (4.03 to 407.87)
Total active moiety after Dose 3182.535 (23.03 to 407.03)
Total active moiety after Dose 4192.100 (6.03 to 406.90)

Adverse events

Collected over Adverse event data was collected from the time of informed consent through the end of study for each subject, Day 120, a total of up to 146 days including the screening and dosing stabilization periods.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Risperidone Followed by PERSERIS0/23 (0%)1/23 (4.3%)9/23 (39.1%)
Most frequent serious events
Most frequent serious events
EventOral Risperidone Followed by PERSERIS
increase in liver enzymesHepatobiliary disorders1/23
Most frequent other events
Most frequent other events
EventOral Risperidone Followed by PERSERIS
upper respiratory tract infectionInfections and infestations3/23
blood prolactin increasedInvestigations2/23
decreased appetiteMetabolism and nutrition disorders2/23
dyskinesiaNervous system disorders2/23
fallInjury, poisoning and procedural complications2/23
headacheNervous system disorders2/23

Baseline characteristics

The baseline number is the number of participants who received oral risperidone during the stabilization period and at least one PERSERIS injection. This equals the number of participants included in the safety and efficacy populations. There was one additional participant included in the PK population who had PK data from oral risperidone but did not receive PERSERIS and was not included in the safety population.

Age, Continuous
Age, Continuous(years)Oral Risperidone Followed by PERSERIS
Mean53.3 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)Oral Risperidone Followed by PERSERIS
Female9
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Risperidone Followed by PERSERIS
Hispanic or Latino3
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Risperidone Followed by PERSERIS
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American17
White5
More than one race0
Unknown or Not Reported0
Body Mass Index
Body Mass Index(kg/m^2)Oral Risperidone Followed by PERSERIS
Mean28.49 ± 4.650
CYP2D6 Genotype
CYP2D6 Genotype(Participants)Oral Risperidone Followed by PERSERIS
Poor0
Intermediate0
Extensive23
Ultra-rapid0
08

Study locations

1 site
  • Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2020, 10 months.

Results were first posted in Jul 2021, 1 year 1 month after primary completion.

Of 88 phase 4 interventional studies under Schizophrenia, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 7, 2019
StartActual
Jun 28, 2019
Primary completionActual
May 12, 2020
CompletionActual
May 12, 2020
Results first posted
Jul 7, 2021
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03978832
Lead sponsor
Indivior Inc.
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Jun 28, 2019
Primary completion
May 12, 2020
Completion
May 12, 2020
Results posted
Jul 7, 2021
Last update
Jul 7, 2021

Study contacts

David Walling
principal investigator · Collaborative Neuroscience Network

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion